1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Colorectal Cancer Research Program (CRCRP) is sponsored by U.S. Department of Defense, Congressionally Directed Medical Research Programs (CDMRP). The CRCRP supports high-impact biomedical research focused on reducing morbidity and mortality of colorectal cancer, with a unique prioritization of early-onset colorectal cancer.
It covers a broad spectrum of research, including prevention, early detection, precision oncology, tumor biology, molecular/genetic risk factors, treatment optimization, survivorship, and technology-enabled patient monitoring. Priority topics include digital risk-stratification tools, telehealth-assisted diagnostics, novel biomarkers, surgical decision-support platforms, adaptive clinical trial methodologies, and disparities research.
Eligibility is broad, including academic centers, universities, non-profits, federally funded R&D centers, and for-profit entities like biotechnology and AI diagnostic firms.
Get alerted about grants like this
Save a search for “U.S. Department of Defense, Congressionally Directed Medical Research Programs (CDMRP)” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Academic medical centers, universities, nonprofit research institutes, federally funded R&D centers, and qualified for-profit entities including biotechnology firms, medical device companies, imaging startups, and AI-enabled diagnostic developers. Applications must articulate clinical/translational value, scientific innovation, and military health relevance. Confirm the full requirements in the official notice before applying.
Colorectal Cancer Research Program (CRCRP) is funded by U.S. Department of Defense, Congressionally Directed Medical Research Programs (CDMRP). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Changing Health Systems Using Evidence-based interventions to increase Colorectal Cancer Screening is sponsored by Centers for Disease Control and Prevention - National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). This funding opportunity supports the implementation of evidence-based interventions to increase colorectal cancer screening. It aims to reduce the burden of cancer through comprehensive and coordinated approaches to policy, systems, and environmental change strategies. The program emphasizes primary prevention, early detection, addressing the needs of cancer survivors, and promoting health equity. New Mexico Department of Health previously received funding for Cancer Prevention and Control Programs.
Changing Health Systems Using Evidence-based interventions to increase Colorectal Cancer Screening (DP25-0012) is sponsored by Centers for Disease Control and Prevention (CDC) - NCCDPHP. This grant aims to increase colorectal cancer screening through evidence-based interventions within health systems. Nonprofit organizations in New Mexico focused on cancer prevention and early detection services would be highly relevant for this opportunity.
The Congressionally Directed Medical Research Programs just released $1.27 billion across 34 programs. Universities, nonprofits, and small businesses are all eligible.
Read articleDoW's 2026 SBIR Broad Agency Announcement now operates on a monthly pre-release / quarterly close cadence. The 42 topics closing June 24 are the first test of whether the new rhythm produces the steady-state deal flow defense innovators have been asking for since 2022.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article